NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/23/2026
Back to search
Official data from USPTO
T G TRAFFIKGENE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
06/23/2026
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
07/22/2024
Registration date
06/23/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/23/2026
Last transaction
06/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Santiago de Compostela, ES
Examiner
KOPENSKI, CLAUDIA ANN
Law office
O20
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a green stylized double helix design with a stylized green letter "T" on the left of the helix and stylized green "G" on the right of the helix. Below is the word "TRAFFIKGENE" in green stylized font.
Holders and representatives
Holders
U. C. (pessoa física)
Representatives
Ricardo Fischer ArentFox Schiff LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biologyother than for medical or veterinary use; Nucleic acidsother than for medical or veterinary purposes; Nucleic recombinant acidsother than for medical or veterinary purposes; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processesother than for medical use; Biological tissue culturesother than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing other than for medical or veterinary purposes; Biological preparationsother than for medical or veterinary purposesbiological preparations for use in industry and sciencethe agriculture and the food industry; Aldehydes; Active chemical ingredients for use in the manufacture of pharmaceuticalstransfection reagents for use in the manufacture of pharmaceuticalsin protein productionthe manufacture of biologicsviral vectors and vaccine productionthe engineering of producer and stable cell lines for drug discovery and preclinical developmentlaboratory kits for use in transfection procedures for use in the manufacture of pharmaceuticalsin protein productionthe manufacture of biologicsviral vectors and vaccine productionthe engineering of producer and stable cell lines for drug discovery and preclinical development which are comprised of a peptide-based transfection reagentnucleic acidsproteinssmall molecules being organic compoundsa combination of these elements for enhancing membrane permeation for the introduction of relevant biological moleculesgene materialproteinspeptidesantibodies inside cultured cells; Salts being chemical preparations in the nature of salts for industrialpharmaceutical and agricultural purposes
Class 5
Pharmaceuticals in the nature of advanced therapeutic medicinal productsnamely RNA therapiesgene and cell therapiesas well as enzyme replacement therapiesimmunotherapiesvaccines all for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; medical preparations in the nature of medical preparations for gene therapyimmunotherapyenzyme replacement and vaccinations all for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; veterinary preparations for gene therapy for pets and farm animalsall for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes being advanced therapeutic medicinal products in the nature of RNA therapy preparationsmRNAsiRNAantisense oligonucleotide therapies for the treatment of cancergenetic disordersinfectious diseasesimmune-mediated diseasesgene therapy preparations for the treatment of inherited genetic disorderscancerrare diseasesenzyme replacement therapies for the treatment of metabolic and lysosomal storage disordersvaccines for prophylactic and therapeutic useimmunotherapies for the treatment of cancerautoimmune diseasesinflammatory diseasescell therapies for the treatment of cancergenetic disordersdegenerative diseases; Medicines for human purposes being RNA therapiesgene and cell therapiesas well as enzyme replacement therapiesimmunotherapiesvaccines all for the treatment of oncological disorders particularly melanoma or lung cancermetabolic diseases particularly lysosomal storage diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Biological preparations for medical purposes for the treatment of rare diseasesgenetic diseasescancer or the prophylaxis of viral diseases; Pharmaceutical preparationsadvanced therapeutic medicinal products being pharmaceuticals for enzyme replacement therapiesimmunotherapiesvaccines for the treatment of oncological disorders particularly melanoma or lung cancermetabolic diseases particularly lysosomal storage diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nutraceutical preparations for therapeutic and medical purposes for the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemical preparations for pharmaceutical purposesfor the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemical preparations for medical purposesnamely for the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemico-pharmaceutical preparations in the nature of formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposesnamely formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nucleic acids for medical or veterinary purposes; Nucleic recombinant acids for medical or veterinary purposes
Class 42
Scientific and technological servicesscientific researchanalysistestingmodelingchemical designsynthesis and characterization as well as related research and design services in the field of bioinformatics and structure-activity relationship researchparticularly that driven by machine learning and related algorithms; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for others for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services in the nature of research and development services in the field of peptide chemistryorganic chemistrysupramolecular chemistry and biological chemistry
Class 44
Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/23/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2026
PUBO
PUBLISHED FOR OPPOSITION
05/05/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/29/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/02/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/23/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/23/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/23/2026
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
02/19/2026
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
02/19/2026
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
02/19/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/13/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/13/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/13/2026
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
01/06/2026
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
01/06/2026
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
01/06/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/18/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/18/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/18/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/14/2025
GNFR
FINAL REFUSAL E-MAILED
10/14/2025
CNFR
FINAL REFUSAL WRITTEN
10/14/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/24/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/24/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/29/2025
GNRT
NON-FINAL ACTION E-MAILED
07/29/2025
CNRT
NON-FINAL ACTION WRITTEN
07/29/2025
DOCK
ASSIGNED TO EXAMINER
07/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/29/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/11/2025
GNRT
NON-FINAL ACTION E-MAILED
02/11/2025
CNRT
NON-FINAL ACTION WRITTEN
02/11/2025
DOCK
ASSIGNED TO EXAMINER
02/11/2025
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/10/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/10/2025
NWAP
NEW APPLICATION ENTERED
07/22/2024
Continuous trademark protection
Get notified about every new filing that threatens T G TRAFFIKGENE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.